Class summary at a glance.

Every drug in the Dopamine-2 Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $20.1Mcombined across class
Total Rx claims: 1.6M670K unique beneficiaries
Generic mfrs (active): 12across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Metoclopramide

Brand: GIMOTI · 1.6M Part D claims (CY24) · 670K beneficiaries · First FDA approval: 1990-09-30

10 generic mfrs 1 plans require PA

Low NADAC$0.039

→

Avg plan cost$0.140

Part D spend $20.1M 4× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Droperidol

42 Part D claims (CY24) · 11 beneficiaries · First FDA approval: 1990-09-30

2 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $987

Class share

of class CY24 spend

View profile →

Amisulpride

Brand: Barhemsys · — Part D claims (CY24) · First FDA approval: 2020-02-27

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.